# Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

> **NCT00225147** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pharming Technologies B.V.** · enrollment: 77 (actual)

## Conditions studied

- Hereditary Angioedema
- Angioneurotic Edema

## Interventions

- **DRUG:** Recombinant Human C1 Inhibitor
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00225147
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-10
- **Final completion:** 2010-01
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2013-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225147, "Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00225147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*